trending Market Intelligence /marketintelligence/en/news-insights/trending/69ggHsRLVFcNHgA_MfGGmA2 content esgSubNav
In This List

XTL Biopharmaceuticals regains compliance with Nasdaq listing rule

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


XTL Biopharmaceuticals regains compliance with Nasdaq listing rule

XTL Biopharmaceuticals Ltd. regained compliance with the minimum $2.5 million stockholders' equity requirement for continued listing on the Nasdaq Capital Market.

Nasdaq determined that the company is compliant with the listing rule after XTL showed that it had stockholders' equity of about $3.6 million as of Sept. 30.